[admin]

Two major studies have raised concerns about GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), widely used for weight loss and diabetes management. Researchers have found that these medications may increase the risk of diabetic retinopathy a serious eye condition caused by damage to blood vessels in the retina in people with type 2 diabetes.

The first study, analysing over 185,000 patients, found a modest increase in retinopathy risk but no significant rise in severe complications like blindness. The second study, which tracked 159,000+ patients, showed a slight increase in the risk of NAION (a rare eye disorder), though the overall risk remained low.

Despite these risks, the drugs have shown major benefits, including up to 20% weight loss and improved blood sugar control. However, side effects such as muscle loss, hair loss, and gastrointestinal issues are also reported, and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is investigating over 100 deaths linked to these injections.

Experts recommend regular eye exams for diabetics on these drugs to catch any eye issues early. Though the risks exist, they are still considered low, and the weight-loss benefits have kept the injections popular.

Source: https://www.medical-specialists.co.uk/n ... hers-warn/